Acceptor-donor-acceptor structured phototheranostics for near-infrared II fluorescent and photoacoustic imaging-guided photodynamic and photothermal synergistic therapy
Multi-modal imaging-guided synergistic photodynamic therapy (PDT) and photothermal therapy (PTT) show great benefits in cancer treatment. The phototheranostics with near-infrared (NIR) absorption, high reactive oxygen species (ROS) generation and photothermal conversion efficiency is highly desirabl...
Gespeichert in:
Veröffentlicht in: | Science China materials 2023, Vol.66 (1), p.385-394 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Multi-modal imaging-guided synergistic photodynamic therapy (PDT) and photothermal therapy (PTT) show great benefits in cancer treatment. The phototheranostics with near-infrared (NIR) absorption, high reactive oxygen species (ROS) generation and photothermal conversion efficiency is highly desirable. Here, we designed and synthesized an “acceptor-donor-acceptor” (A-D-A) structured molecule named IDCIC, with strong absorbance in the NIR region. We further prepared IDCIC into water-soluble nanoparticles (NPs) by wrapping with 1,2-distearoylsn-glycero-3-phosphoethanolamine-
N
-[(polyethylene glycol)-2000]-amine (DSPE-PEG2000-NH
2
). The obtained IDCIC NPs show an NIR absorption peak at 760 nm and an NIR-II fluorescence spectrum peak at ∼1000 nm with a fluorescent quantum yield of 1.2%, enabling them excellent photoacoustic and NIR-II fluorescent imaging capabilities. Moreover, IDCIC NPs could simultaneously generate singlet oxygen (with a quantum yield of 9.1%), hydroxyl radicals (·OH) and heat (with a photothermal conversion efficiency of 78.9%) under 808-nm laser irradiation. Based on the above-mentioned properties, IDCIC NPs were used for dual-modal imagingguided synergistic photodynamic/photothermal therapy of cancer. |
---|---|
ISSN: | 2095-8226 2199-4501 |
DOI: | 10.1007/s40843-022-2143-2 |